Literature DB >> 24004675

Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.

Lorena Fontán1, Ari Melnick.   

Abstract

MALT1 mediates the activation of NF-κB in response to antigen receptor signaling. MALT1, in association with BCL10 and CARD11, functions as a scaffolding protein to activate the inhibitor of IκB kinase (IKK) complex. In addition, MALT1 is a paracaspase that targets key proteins in a feedback loop mediating termination of the NF-κB response, thus promoting activation of NF-κB signaling. Activated B-cell subtype of diffuse large B-cell lymphomas (ABC-DLBCL), which tend to be more resistant to chemotherapy, are often biologically dependent on MALT1 activity. Newly developed MALT1 small-molecule inhibitors suppress the growth of ABC-DLBCLs in vitro and in vivo. This review highlights the recent advances in the normal and disease-related functions of MALT1. Furthermore, recent progress targeting MALT1 proteolytic activity raises the possibility of deploying MALT1 inhibitors for the treatment of B-cell lymphomas and perhaps autoimmune diseases that involve increased B- or T-cell receptor signaling. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24004675     DOI: 10.1158/1078-0432.CCR-12-3869

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

2.  MALT1 Inhibitors May Potentially Treat Lymphomas and Autoimmune Disorders.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2016-02-01       Impact factor: 4.345

Review 3.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

4.  Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities.

Authors:  Trong D Tran; Brice A P Wilson; Curtis J Henrich; Louis M Staudt; Lauren R H Krumpe; Emily A Smith; Jarrod King; Karen L Wendt; Alberto M Stchigel; Andrew N Miller; Robert H Cichewicz; Barry R O'Keefe; Kirk R Gustafson
Journal:  J Nat Prod       Date:  2019-01-02       Impact factor: 4.050

5.  Optimizing multiple sclerosis diagnosis: gene expression and genomic association.

Authors:  Michael Gurevich; Gadi Miron; Anat Achiron
Journal:  Ann Clin Transl Neurol       Date:  2015-02-06       Impact factor: 4.511

6.  Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.

Authors:  Yu Ma; Ziwei Liao; Yi Xu; Ziyun Zhong; Xu Wang; Fan Zhang; Shaohua Chen; Lijian Yang; Gengxin Luo; Xin Huang; Suming Huang; Xiuli Wu; Yangqiu Li
Journal:  Eur J Med Res       Date:  2014-11-11       Impact factor: 2.175

7.  Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia.

Authors:  Yi Xu; Junyan Hu; Xu Wang; Li Xuan; Jing Lai; Ling Xu; Shaohua Chen; Lijian Yang; Gengxin Luo; Kanger Zhu; Xiuli Wu; Yangqiu Li
Journal:  Cancer Cell Int       Date:  2015-07-25       Impact factor: 5.722

8.  TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways.

Authors:  Wenzhi Shen; Renle Du; Jun Li; Xiaohe Luo; Shuangtao Zhao; Antao Chang; Wei Zhou; Ruifang Gao; Dehong Luo; Juan Wang; Na Hao; Yanhua Liu; Yanan Chen; Yunping Luo; Peiqing Sun; Shengyong Yang; Na Luo; Rong Xiang
Journal:  Signal Transduct Target Ther       Date:  2016-07-22

9.  How Biophysical Forces Regulate Human B Cell Lymphomas.

Authors:  F Apoorva; Alexander M Loiben; Shivem B Shah; Alberto Purwada; Lorena Fontan; Rebecca Goldstein; Brian J Kirby; Ari M Melnick; Benjamin D Cosgrove; Ankur Singh
Journal:  Cell Rep       Date:  2018-04-10       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.